Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 458 participants.

Also called NCT01196819

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 458 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01196819
Other papers using this trial's data
  • A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2013-05-20 DOI, PubMed 23685298
  • [Long term safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of coronary de novo lesions] Zhonghua xin xue guan bing za zhi, 2017-11-24 DOI, PubMed 29166720

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01196819. Randomized; double masking; primary purpose treatment. Start 2010-09 (actual); primary completion 2012-05 (actual). Results posted on 2018-02-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Randomized MicroPort's Firehawk DES Versus Xience V: TARGET I Trial
Intervention (Device)
Firehawk
Intervention (Device)
Xience V
Lead sponsor
Shanghai MicroPort Medical (Group) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01196819
Content hash
491df589ccdd5353e46e6ba7a81b9d1c83bd9075174dbe6e51ab0636a38562a5